Effect of hyaluronic acid on urine nerve growth factor in cyclophosphamide-induced cystitis

International Journal of Urology

Volumn 18, Issue 7, 2011, Pages 525-531

  Ho, Dong Ru ^a,b,c   Chen, Chih Shou ^a   Lin, Wei Yu ^a,b,c   Chang, Pey Jium ^b   Huang, Yun Chin ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

Cyclophosphamide; Cystitis; Hyaluronic acid; Nerve growth factor

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE; H 3631; HYALURONIC ACID; HYALURONIDASE; NERVE GROWTH FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER FUNCTION; CONTROLLED STUDY; CYSTITIS; CYSTOMETRY; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; MICTURITION REFLEX; NONHUMAN; OVERACTIVE BLADDER; PRIORITY JOURNAL; TRICHOME; URINE; URODYNAMICS;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; CYSTITIS; DISEASE MODELS, ANIMAL; FEMALE; HYALURONIC ACID; MUCOUS MEMBRANE; NERVE GROWTH FACTOR; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; URINARY BLADDER; URINARY BLADDER, OVERACTIVE; VISCOSUPPLEMENTS;

EID: 79959547498     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2011.02779.x     Document Type: Article

References (36)

1. Juszczak K, Krolczyk G, Filipek M, Dobrowolski ZF, Thor PJ. Animal models of overactive bladder: cyclophosphamide (CYP)-induced cystitis in rats. Folia Med. Cracov. 2007; 48: 113-23.
2. Parsons CL, Greene RA, Chung M, Stanford EJ, Singh G. Abnormal urinary potassium metabolism in patients with interstitial cystitis. J. Urol. 2005; 173: 1182-5.
3. Parsons CL. The role of the urinary epithelium in the pathogenesis of interstitial cystitis/prostatitis/urethritis. Urology 2007; 69 (4 Suppl): 9-16.
4. Dell JR, Butrick CW. Multimodal therapy for painful bladder syndrome/interstitial cystitis. J. Reprod. Med. 2006; 51 (3 Suppl): 253-60.
5. Gill WB, Jones KW, Ruggiero KJ. Protective effects of heparin and other sulfated glycosaminoglycans on crystal adhesion to injured urothelium. J. Urol. 1982; 127: 152-4.
6. Barrington JW, Stephenson TP. Pentosanpolysulphate for interstitial cystitis. Int. Urogynecol. J. Pelvic Floor Dysfunct. 1997; 8: 293-5.
7. Parsons CL, Pollen JJ, Anwar H, Stauffer C, Schmidt JD. Antibacterial activity of bladder surface mucin duplicated in the rabbit bladder by exogenous glycosaminoglycan (sodium pentosanpolysulfate). Infect. Immun. 1980; 27: 876-81.
8. Jang J, Park EY, Seo SI, Hwang TK, Kim JC. Effects of intravesical instillation of cyclooxygenase-2 inhibitor on the expression of inducible nitric oxide synthase and nerve growth factor in cyclophosphamide-induced overactive bladder. BJU Int. 2006; 98: 435-9.
9. Bjorling DE, Jacobsen HE, Blum JR etal. Intravesical Escherichia coli lipopolysaccharide stimulates an increase in bladder nerve growth factor. BJU Int. 2001; 87: 697-702.
10. Yokoyama T, Kumon H, Nagai A. Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder. Neurourol. Urodyn. 2007; 27: 417-20.
11. Gonzalez RR, Fong T, Belmar N, Saban M, Felsen D, Te A. Modulating bladder neuro-inflammation: RDP58, a novel anti-inflammatory peptide, decreases inflammation and nerve growth factor production in experimental cystitis. J. Urol. 2005; 173: 630-4.
12. Steers WD. Pathophysiology of overactive bladder and urge urinary incontinence. Rev. Urol. 2002; 4 (Suppl 4): S7-18.
13. Rattray M. Is there nicotinic modulation of nerve growth factor? Implications for cholinergic therapies in Alzheimer's disease. Biol. Psychiatry 2001; 49: 185-93.
14. Hoener MC, Hewitt E, Conner JM, Costello JW, Varon S. Nerve growth factor (NGF) content in adult rat brain tissues is several-fold higher than generally reported and is largely associated with sedimentable fractions. Brain Res. 1996; 728: 47-56.
15. Juszczak K, Ziomber A, Wyczolkowski M, Thor PJ. Hyperosmolarity alters micturition: a comparison of urinary bladder motor activity in hyperosmolar and cyclophosphamide-induced models of overactive bladder. Can. J. Physiol. Pharmacol. 2010; 88: 899-906.
16. Jacobs BL, Smaldone MC, Tyagi V etal. Increased nerve growth factor in neurogenic overactive bladder and interstitial cystitis patients. Can. J. Urol. 2010; 17: 4989-94.
17. Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women. BJU Int. 2008; 102: 1440-4.
18. Liu HT, Kuo HC. Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J. Urol. 2008; 179: 2270-4.
19. Liu HT, Kuo HC. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. Urology 2008; 72: 104-8.
20. Liu HT, Chancellor MB, Kuo HC. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int. 2009; 103: 1668-72.
21. Liu HT, Kuo HC. Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention. Neurourol. Urodyn. 2009; 28: 78-81.
22. Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur. Urol. 2009; 56: 700-6.
23. Kuo HC, Liu HT, Chancellor MB. Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. Neurourol. Urodyn. 2010; 29: 482-7.
24. Porru D, Cervigni M, Nasta L etal. Results of endovesical hyaluronic acid/chondroitin sulfate in the treatment of Interstitial Cystitis/Painful Bladder Syndrome. Rev. Recent Clin. Trials 2008; 3: 126-9.
25. Riedl CR, Engelhardt PF, Daha KL, Morakis N, Pfluger H. Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. Int. Urogynecol. J. Pelvic Floor Dysfunct. 2008; 19: 717-21.
26. Kallestrup EB, Jorgensen SS, Nordling J, Hald T. Treatment of interstitial cystitis with Cystistat: a hyaluronic acid product. Scand. J. Urol. Nephrol. 2005; 39: 143-7.
27. Ito K, Iwami A, Katsura H, Ikeda M. Therapeutic effects of the putative P2X3/P2X2/3 antagonist A-317491 on cyclophosphamide-induced cystitis in rats. Naunyn Schmiedebergs Arch. Pharmacol. 2008; 377: 483-90.
28. Ahmad I, Sarath KN, Meddings RN. Sequential hydrodistension and intravesical instillation of hyaluronic acid under general anaesthesia for treatment of refractory interstitial cystitis: a pilot study. Int. Urogynecol. J. Pelvic Floor Dysfunct. 2008; 19: 543-6.
29. Eichel L, Scheidweiler K, Kost J etal. Assessment of murine bladder permeability with fluorescein: validation with cyclophosphamide and protamine. Urology 2001; 58: 113-18.
30. Kimura M, Tomita Y, Morishita H, Takahashi K. Presence of mucosal change in the urinary bladder in nonhematuric patients with long-term exposure and/or accumulating high-dose cyclophosphamide. Possible significance of follow-up cystoscopy on preventing development of cyclophosphamide-induced hemorrhagic cystitis. Urol. Int. 1998; 61: 8-11.
31. Kyung YS, Park HY, Lee G. Preservation of uroplakins by 2-mercaptoethanesulfonate in cyclophosphamide-induced rat cystitis. Arch. Toxicol. 2010; 85: 51-7.
32. Lima MV, Ferreira FV, Macedo FY, Brito GA, Ribeiro RA. Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis. Cancer Chemother. Pharmacol. 2007; 59: 643-50.
33. Andersson MC, Tobin G, Giglio D. Cholinergic nitric oxide release from the urinary bladder mucosa in cyclophosphamide-induced cystitis of the anaesthetized rat. Br. J. Pharmacol. 2008; 153: 1438-44.
34. Chuang YC, Yoshimura N, Huang CC, Wu M, Chiang PH, Chancellor MB. Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats. Eur. Urol. 2009; 56: 159-66.
35. Heese K, Inoue N, Sawada T. NF-kappaB regulates B-cell-derived nerve growth factor expression. Cell Mol. Immunol. 2006; 3: 63-6.
36. Heese K, Beck KF, Behrens MH etal. Effects of high glucose on cytokine-induced nerve growth factor (NGF) expression in rat renal mesangial cells. Biochem. Pharmacol. 2003; 65: 293-301.